national patient safety goal 3e: anticoagulation
DESCRIPTION
National Patient Safety Goal 3E: Anticoagulation. Purpose of National Patient Safety Goals (NPSG):. Promote improvements in patient safety Highlight problem areas in health care Describe evidence-based solutions Focus on system-wide solutions. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: National Patient Safety Goal 3E: Anticoagulation](https://reader035.vdocuments.site/reader035/viewer/2022062518/5681489a550346895db5af8d/html5/thumbnails/1.jpg)
National Patient Safety Goal 3E:
Anticoagulation
![Page 2: National Patient Safety Goal 3E: Anticoagulation](https://reader035.vdocuments.site/reader035/viewer/2022062518/5681489a550346895db5af8d/html5/thumbnails/2.jpg)
Purpose of National Patient Safety Goals (NPSG):
• Promote improvements in patient safety
• Highlight problem areas in health care
• Describe evidence-based solutions
• Focus on system-wide solutions
![Page 3: National Patient Safety Goal 3E: Anticoagulation](https://reader035.vdocuments.site/reader035/viewer/2022062518/5681489a550346895db5af8d/html5/thumbnails/3.jpg)
National Patient Safety Goals
• Goals and Requirements are developed by experts
• Approved by the JC’s Board in June 2007
![Page 4: National Patient Safety Goal 3E: Anticoagulation](https://reader035.vdocuments.site/reader035/viewer/2022062518/5681489a550346895db5af8d/html5/thumbnails/4.jpg)
National Patient Safety Goal 3E: Anticoagulation
• Reduce the likelihood of patient harm with the use of anticoagulation (AC) therapy.
• Applies to multiple inpatient and outpatient settings
• Rationale: Anticoagulation therapy is a high risk treatment
![Page 5: National Patient Safety Goal 3E: Anticoagulation](https://reader035.vdocuments.site/reader035/viewer/2022062518/5681489a550346895db5af8d/html5/thumbnails/5.jpg)
Risks with Anticoagulant Therapy
• Anticoagulants listed as one of the top 5 drug Classes with patient safety incidents¹
• Reported meds involved in harmful events²:
– #3 Heparin, #6 Warfarin, #9 Enoxaparin
• Enoxaparin medication related deaths reported to MedMarx in 2005²
• Heparin errors typically involve infusion pump and IVdelivery errors³
1. Cousins D et al. 20062. USP MedMarx data, 20053. Fanikos J. et al. 2004
![Page 6: National Patient Safety Goal 3E: Anticoagulation](https://reader035.vdocuments.site/reader035/viewer/2022062518/5681489a550346895db5af8d/html5/thumbnails/6.jpg)
National Patient Safety Goal 3E:
• Applies to the use of Heparin, low molecular weight heparins, warfarin and other anticoagulants
• One year phase-in period with full implementation by January 1, 2009.
![Page 7: National Patient Safety Goal 3E: Anticoagulation](https://reader035.vdocuments.site/reader035/viewer/2022062518/5681489a550346895db5af8d/html5/thumbnails/7.jpg)
NPSG 3E – Timeline:
• April 1, 2008 - assigned coordination of NPSG 3E
• July 1, 2008 - implementation work plan & timeline
• October 1, 2008, pilot testing in one unit
• January 1, 2009 - process fully implemented
![Page 8: National Patient Safety Goal 3E: Anticoagulation](https://reader035.vdocuments.site/reader035/viewer/2022062518/5681489a550346895db5af8d/html5/thumbnails/8.jpg)
Surveying and Scoring NPSG’s:
• Evaluate actual performance
• All requirements must be implemented
• Compliant or Not Compliant
• Failure to comply will result in a “Requirement for Improvement (RFI)”
![Page 9: National Patient Safety Goal 3E: Anticoagulation](https://reader035.vdocuments.site/reader035/viewer/2022062518/5681489a550346895db5af8d/html5/thumbnails/9.jpg)
NPSG 3E: Anticoagulation
For more information, see the Joint Commission Website:www.jointcommission.org
References:
1. Cousins D et al. 2006. Risk assessment of anticoagulation therapy. National Patient Safety Agency. United Kingdom
2. USP MedMarx data, 20053. Fanikos J. et al. Medication errors associated with
anticoagulant therapy in the hospital. Am J Cardiol. 2004; 94: 532-5.
![Page 10: National Patient Safety Goal 3E: Anticoagulation](https://reader035.vdocuments.site/reader035/viewer/2022062518/5681489a550346895db5af8d/html5/thumbnails/10.jpg)
DVT/PE Prophylaxis
![Page 11: National Patient Safety Goal 3E: Anticoagulation](https://reader035.vdocuments.site/reader035/viewer/2022062518/5681489a550346895db5af8d/html5/thumbnails/11.jpg)
Procedure related risk DVT/PE
Level of Risk
Calf DVT Proximal DVT
Clinical PE
Fatal PE
Low 2% 0.4% 0.2% 0.002%
Moderate 10%-20% 2%-4% 1%-2% 0.1%-0.4%
High 20%-40% 4%-8% 2%-4% 0.4%-1%
Very High 40%-80% 10%-20% 4%-10% 0.2%-0.5%
ICSI: Venous Thromboembolism ProphylaxisFourth Edition/June 2007
![Page 12: National Patient Safety Goal 3E: Anticoagulation](https://reader035.vdocuments.site/reader035/viewer/2022062518/5681489a550346895db5af8d/html5/thumbnails/12.jpg)
Medical Condition Risk DVT
Condition Risk of DVT
General Medical 10%-26%
MI 17%-34%
Stroke 11%-75%
CHF 20%-40%
Medical ICU 35%-42%
Chest 2005; 128;958-969
![Page 13: National Patient Safety Goal 3E: Anticoagulation](https://reader035.vdocuments.site/reader035/viewer/2022062518/5681489a550346895db5af8d/html5/thumbnails/13.jpg)
Percent of Patients Receiving Appropriate DVT Prophylaxis
WoodwindsSt Joseph’s
Total
Med
Surg
25%
50%
75%
54%
38%
66%
31%
45%
38%
Audit Jan 2008
![Page 14: National Patient Safety Goal 3E: Anticoagulation](https://reader035.vdocuments.site/reader035/viewer/2022062518/5681489a550346895db5af8d/html5/thumbnails/14.jpg)
Percent of High Risk Patients 0n Appropriate DVT Prophylaxis
WoodwindsSt Joseph’s
Total
Med
Surg
25%
50%
75%
WoodwindsSt Joseph’s
Audit Jan 2008